title: South African experts comment on FDA approval of dabigatran in atrial fibrillation.
authors.forename: E
authors.initials: E
authors.lastname: Klug
authors.forename: A
authors.initials: A
authors.lastname: Bryer
authors.forename: J
authors.initials: J
authors.lastname: Aalbers
mesh_terms: D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000627:therapeutic use*; D000069604:Dabigatran; D017277:Drug Approval; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D013019:South Africa; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D015091:beta-Alanine; D000069604:Dabigatran